Assembly Biosciences Announces June Conference Presentations
May 26, 2017
• Jefferies 2017 Global Healthcare Conference -
*A webcast of the corporate presentation will be available in the Investor Relations section of the Company's website at www.assemblybio.com
• Microbiome Drug Development Summit -
Separately, the company announced grants of options to purchase 89,750 shares of Assembly's common stock with an exercise price of
The stock options were granted outside of Assembly's stockholder-approved equity incentive plan pursuant to Assembly's 2017
Inducement Award Plan. The stock options were approved by the Compensation Committee of the Board of Directors, which is comprised solely of independent directors, as an inducement material to the employees entering into employment with Assembly in accordance with NASDAQ Listing Rule 5635(c)(4), which requires this public announcement.
advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit www.assemblybio.com.
The information in this press release contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of Assembly's development programs. Certain forward-looking statements may be identified by reference to a future period or periods or by use of forward-looking terminology such as "designed" or "developing." Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Assembly are more fully detailed under the heading "Risk Factors" in Assembly's Annual Report on
Form 10-K for the year ended
Assembly Biosciences, Inc.Investors: Lauren Glaser(415) 521-3828 email@example.com Media: Barbara Lindheim(212) 584-2276 firstname.lastname@example.org
News Provided by Acquire Media
« back to news page